- Ardena supported the development and GMP manufacturing of CYRS1542, enabling its progression into Phase 1 clinical trials.
- Cyrus Therapeutics received IND approvals from the US FDA and MFDS in 2025 to initiate first-in-human studies.
Ardena has contributed to the advancement of CYRS1542, a molecular glue degrader developed by Cyrus Therapeutics, into Phase 1 clinical development. The program received Investigational New Drug (IND) approvals from the US FDA and the Korean Ministry of Food and Drug Safety in 2025, allowing first-in-human studies to begin.
Ardena, operating as a CDMO and contract manufacturing partner, was responsible for formulation development of oral dosage forms and the GMP manufacturing of clinical trial materials. This work supported the transition from preclinical development to clinical evaluation.
The company’s role focused on ensuring consistent product performance and readiness for clinical use. Its integrated capabilities in formulation and manufacturing enabled the delivery of drug product suitable for early-stage clinical studies.
“We are pleased to support Cyrus Therapeutics in bringing CYRS1542 into clinical development. Our teams collaborated closely on formulation and GMP manufacturing to deliver a drug product suitable for first-in-human studies.”
Jeremie Trochu, CEO of Ardena
